AuraMedics` Generic Lifitegrast Receives Approval in the U.S.
Bausch + Lomb Announces Expiration of Hart-Scott-Rodino Waiting Period for Acquisition of XIIDRA®
Micro Labs' Generic Lifitegrast Receives Approval in US
June 30 (Reuters) - Bausch + Lomb (BLCO.TO) said on Friday it would acquire several Novartis (NOVN.S) eye-care products for $1.75 billion as their market grows, sending the company's shares up over 8% in early trading.
The slim-down at Novartis continues, with some eye disease products now reportedly on the chopping block.
Ingenus' Generic Lifitegrast Receives Approval in the U.S.
Sun's Generic Lifitegrast Receives Approval in the U.S.
Enforcement Report - Week of June 15, 2022
TOKYO (Reuters) - Takeda Pharmaceutical Co Ltd (4502.T) said on Monday it anticipates an operating loss of about $200 million related to Novartis AG’s decision to withdraw a marketing application for the dry-eye drug Xiidra.
Novartis last year bought Shire’s dry eye drug Xiidra from Takeda to beef up its ophthalmic offerings and reap blockbuster sales along the way. But now, the $3 billion-plus buy doesn't look so appealing.